Cagrilintide
$30.00
Cagrilintide (Long-Acting Amylin Analogue / DACRA)
Description:
Cagrilintide is a synthetic, long-acting amylin analogue modified to act as a dual amylin receptor / calcitonin receptor agonist (DACRA). It is being developed as a therapeutic candidate for weight loss and metabolic regulation by modulating satiety, gastric emptying, and energy balance. PubMed+2creative-peptides.com+2
Key Benefits & Potential Applications:
Suppresses appetite and reduces caloric intake creative-peptides.com+2The Lancet+2
Slows post-meal gastric emptying to promote satiety and reduce hunger signals The Lancet+3Peptides+3New England Journal of Medicine+3
Improves glycemic control and metabolic markers in overweight or diabetic subjects New England Journal of Medicine+2The Lancet+2
Has shown significant bodyweight reductions in clinical trials of overweight/obese participants The Lancet+2PubMed+2
When combined with semaglutide (as the “CagriSema” formulation), exhibits enhanced efficacy over monotherapy in weight loss and glucose regulation Wikipedia+2New England Journal of Medicine+2
Mechanism of Action:
Cagrilintide binds to and activates amylin receptors (AMY₁, AMY₂, AMY₃) and calcitonin receptors, leveraging both pathways to regulate appetite, slow gastric motility, and influence energy homeostasis. PubMed+3New England Journal of Medicine+3Wikipedia+3 Its dual receptor activity helps amplify anorectic (appetite-suppressing) signals, thereby reducing food intake and improving metabolic efficiency.
Pharmacokinetics & Structural Highlights:
Designed as a long-acting acylated analogue, prolonging duration of action compared to native amylin peptides. creative-peptides.com+2PubMed+2
Clinical dosing in trials has been once weekly for weight management. Wikipedia+3The Lancet+3New England Journal of Medicine+3
In combination studies with semaglutide, weight loss over 68 weeks reached ~20.4% mean reduction with CagriSema (versus lower values for monotherapies). Wikipedia+1
Research & Clinical Status:
Cagrilintide remains in clinical development and has not yet been approved for general use. New England Journal of Medicine+2PubMed+2 Ongoing investigations include its use as a monotherapy or as part of combination regimens (e.g. with GLP-1 agonists) for obesity and type 2 diabetes. New England Journal of Medicine+2Wikipedia+2
Storage & Handling:
Store lyophilized powder at –20 °C, protected from light and moisture. After reconstitution, maintain the solution refrigerated (2–8 °C) and use within a defined stability window (per lab protocols).
Disclaimer:
For laboratory and investigational use only. Not for human consumption.